Please select the eligibility criteria that correspond to the clinical trial below.
Title: Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the TearCare® System in the Treatment of the Signs and Symptoms of Dry Eye Disease
Brief Summary: In this study, the TearCare System will be compared with the LipiFlow Thermal Pulsation System in patients with dry eye disease. The objective is to demonstrate that the TearCare System is safe and effective in relieving the signs and symptoms of dry eye disease.

NOTE: All sites have been selected for this study. We are not seeking additional sites at this time.


Options:
A: Inclusion Criteria:

* All patients with meibomian gland dysfunction requiring treatment (defined below),
* who have given their written consent to the study.
* Meibomian gland dysfunction requiring treatment is classified by us as:
* Speed score\> 7, Lipiview \<61 nm, MGE \<5 of 15 open glands

Exclusion Criteria:

* Excluded are patients who, due to other diseases would not be able to fulfill the follow-up appointments or give an informed consent to the study
* Systemic medication with tetracyclin derivatives, antihistamines, isotretinoin, or nutritional supplements for MGD that started \<3 months before baseline examination
* Topical cyclosporine-A or steroids that started \<1 month before baseline examination
* Ocular surgery or trauma \<3 months before baseline examination
* Any eyelid abnormalities
* Systemic diseases resulting in dry eye.
B: Inclusion Criteria:

* Men or women ≥18 years old
* Patients affected by age-related cataract \<3 according to the Lens Opacities Classification System III scale (LOCS III)
* Meibomian gland dysfunction (MGD) diagnosed using slit lamp examination, following the criteria reported in the paper Arita R. et al, Am J Ophthalmol. 2016 Sep;169:125-137.
* Fluorescein tear BUT \<7 seconds

Exclusion Criteria:

* Subjects with documented history and / or clinical signs of concomitant presence of an eye infection caused by viruses such as herpes simplex virus (HSV) or fungi in the previous 3 months.
* Patients with anterior blepharitis or Demodex
* Meibomian gland atrophy score greater than 2/3
* Subject treated with drugs that can have effects on MGD prior to inclusion in the study
* Active ocular inflammation or history of chronic eye inflammation recurrent in the previous 3 months (e.g. retinitis, macular inflammation, choroiditis, uveitis, iritis, scleritis, episcleritis, keratitis)
* Eyelid abnormalities affecting eyelid function (entropion, ectropion, neoplasia, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis)
* Abnormalities of the ocular surface that compromise the integrity of the cornea (e.g.

previous chemical burn, recurrent corneal erosion, corneal epithelial defect, corneal dystrophy)

* Subjects who underwent eye surgery in the previous 3 months, including intraocular, oculo-plastic, corneal or refractive surgery
* Patients suffering from diabetes mellitus, rheumatism, immune diseases and other serious systemic diseases
* Pregnant or lactating women
C: Key Inclusion Criteria:

* At least 22
* Subject has dry eye symptoms and uses artificial tears/lubricants regularly
* Subject has moderate to severe symptoms based on a dry eye questionnaire
* Subject has an abnormal tear break-up time
* Subject's eyelid glands secrete a low amount of meibum
* Best corrected visual acuity 20/100 or better
* Willing and able to comply with protocol
* Willing and able to provide consent
* English-speaking

Key Exclusion Criteria:

* Use of medications that treat dry eye disease or that are known to cause ocular dryness.
* Use of topical ophthalmic antibiotics, anti-glaucoma medications, steroids, NSAIDs
* Prior office-based dry eye treatment within the past 12 months, gland expression within the past 6 months, debridement within the past 3 months, punctal plus within 30 days, TrueTear within the past 2 weeks, or meibomian gland probing.
* History of eyelid, conjunctival or corneal surgery within the past year.
* Contact lens use within past 2 weeks
* Ocular conditions or diseases that could limit the safety or effectiveness of the study treatment.
D: Inclusion Criteria:

1. Eyelids must present with blocked meibomian gland openings (plugs), at least 1 visible MG plug in the 4 eyelids, or discernable change in consistency of meibum (increased in viscosity or opacity) when MG expressed in upper or lower eyelids.
2. At least one out of 8 questions on dry eye symptoms is answered with often or all the time.
3. Eyes should not show any other ocular surface pathology which required more treatment than eye lubricant and conventional eyelid hygiene.

Exclusion Criteria:

1. Known history of thyroid disorders (diagnosed by physician).
2. No ocular surgery within the previous 6 months and LASIK within the previous 1 year.
3. Any intake of central nervous system and hormonal drugs within last 30 days and inability to withhold such drugs for at least 6 weeks.
4. Active ocular infection or pterygium.
5. Anticipated necessity to wear contact lens in the duration of the study.
6. Living in the same household as another participant of the study.
7. Any other specified reason as determined by clinical investigator, for example, the need to use any treatment or eyedrops not permitted by the study.

Answer: C